Micardis and Ceftriaxone drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Micardis (telmisartan) and Ceftriaxone (ceftriaxone sodium). Common drug interactions include stridor among females and pyrexia among males.

The phase IV clinical study analyzes what interactions people have when they take Micardis and Ceftriaxone. It is created by eHealthMe based on reports of 50 people who take the same drugs from the FDA, and is updated regularly.

What is Micardis?

Micardis has active ingredients of telmisartan. It is often used in high blood pressure. eHealthMe is studying from 27,605 Micardis users. Check the latest studies of Micardis.

What is Ceftriaxone?

Ceftriaxone has active ingredients of ceftriaxone sodium. It is often used in typhoid fever. eHealthMe is studying from 40,991 Ceftriaxone users. Check the latest studies of Ceftriaxone.



On Aug, 05, 2026

50 people who take Micardis and Ceftriaxone together, and have interactions are studied.

Micardis and Ceftriaxone drug interactions.

What are the common drug interactions of Micardis and Ceftriaxone, by gender? *:

female:

  1. Stridor
  2. Swelling face
  3. Swollen tongue (swelling of tongue)
  4. Anaemia macrocytic (a macrocytic class of anaemia)
  5. Atypical pneumonia (acute respiratory disease marked by high fever and coughing)
  6. Blood pressure decreased
  7. Cardiac arrest
  8. Cardiogenic shock (inadequate circulation of blood)
  9. Chest pain
  10. Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection)

male:

  1. Pyrexia (fever)
  2. Cardiac failure
  3. Eosinophil count increased
  4. Fall
  5. Interstitial lung disease
  6. Lung disorder (lung disease)
  7. Oculomucocutaneous syndrome (a condition characterized by keratoconjunctivitis sicca and by scarring, fibrosis, metaplasia, and shrinkage of the conjunctiva;)
  8. Pneumonia
  9. Pneumothorax (the presence of air or gas in the cavity between the lungs and the chest wall, causing collapse of the lung)
  10. Pneumothorax traumatic

What are the common drug interactions of Micardis and Ceftriaxone, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Eosinophil count increased
  2. Lung disorder (lung disease)
  3. Pruritus (severe itching of the skin)
  4. Rash
  5. Herpes zoster
  6. Pancreatic mass
  7. Rhabdomyolysis (a condition in which damaged skeletal muscle tissue breaks down)

50-59:

  1. Tachycardia (a heart rate that exceeds the range of 100 beats/min)
  2. Blood creatine phosphokinase increased
  3. Chronic kidney disease
  4. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  5. Female genital tract fistula (passage in genital tract of female)
  6. Hepatic enzyme increased
  7. Hepatocellular injury (liver injury)
  8. Insomnia (sleeplessness)
  9. Platelet count decreased
  10. Renal failure (kidney dysfunction)

60+:

  1. Cardiac failure
  2. Pneumonia
  3. Hypocalcaemia (levels of calcium in blood serum are abnormally low)
  4. Injection site erythema (redness at injection site)
  5. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)
  6. Oedema peripheral (superficial swelling)
  7. Oesophageal rupture (break in oesophagus)
  8. Pleural effusion (water on the lungs)
  9. Rash
  10. Relapsing fever (bacterial infection characterized by recurring episodes of fever, headache, muscle and joint aches, and nausea)

What are the existing conditions these people have? *

  1. Pneumonia: 8 people, 16.00%
  2. Gastritis (inflammation of stomach): 8 people, 16.00%
  3. Cardiac Failure: 8 people, 16.00%
  4. Constipation: 7 people, 14.00%
  5. Fever: 7 people, 14.00%
  6. Hypoalbuminaemia (levels of albumin in blood serum are abnormally low): 6 people, 12.00%
  7. Hypocalcaemia (levels of calcium in blood serum are abnormally low): 6 people, 12.00%
  8. Diarrhea: 5 people, 10.00%
  9. Injection Site Erythema (redness at injection site): 5 people, 10.00%
  10. Dry Eyes (lack of adequate tears): 5 people, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Micardis and Ceftriaxone?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Micardis and Ceftriaxone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Micardis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ceftriaxone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Micardis and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ceftriaxone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on telmisartan and ceftriaxone sodium (the active ingredients of Micardis and Ceftriaxone, respectively), and Micardis and Ceftriaxone (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: